Li, Zhuoran
Wang, Jianyang
Deng, Lei
Zhai, Yirui
Zhang, Tao
Bi, Nan
Wang, Jingbo
Wang, Xin
Liu, Wenyang
Xiao, Zefen
Chen, Dongfu
Lv, Jima
Feng, Qinfu
Wang, Wenqing
Zhou, Zongmei
Funding for this research was provided by:
National Natural Science Foundation of China (82071759)
Beijing Hope Run Special Fund of Cancer Foundation of China (LC2020A14)
Article History
Received: 18 February 2024
Accepted: 24 June 2024
First Online: 26 July 2024
Declarations
:
: The study protocol was approved by the Ethics Committee of our hospital (17/094-7845). Board Name: National GCP Center for Anticancer Drugs, The Independent Ethics Committee. Board Affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Informed consent to participate was obtained from all of the participants in the study.
: Not applicable.
: The authors declare no competing interests.